Key result
Statin therapy was associated with less progression of aortic stenosis, with an annualized reduction in aortic valve area of 0.06 cm2 compared to 0.11 cm2 in patients not taking statins.
Why the study?
Does statin therapy reduce the progression of aortic stenosis in patients with mild-moderate calcific aortic stenosis?
Observational (n=174)
Does statin therapy reduce the progression of aortic stenosis in patients with mild-moderate calcific aortic stenosis?
Answers are grounded in this paper and cite their sources.
Preliminary retrospective data suggest that statin therapy may reduce the echocardiographic progression of mild-to-moderate calcific aortic stenosis.
Numerous benefits have been reported for the statin class of drugs in addition to prevention of coronary events. These include reduction of strokes, peripheral vascular disease, dementia, and macular degeneration. Although a common mechanism for these disparate clinical effects is not clear, one hypothesis focuses on the anti-inflammatory effects now recognized as probable actions of the statins. We are now presented with yet another addition to the catalogue of salutary results attained with the statins. In what must be regarded as preliminary but very provocative findings, it has been reported that statins appear to reduce the progression of aortic stenosis.1 The authors of this retrospective study reviewed the course of 174 patients with mild-moderate calcific aortic stenosis over a mean interval of 21 months. Serial echocardiographic assessment demonstrated that patients receiving statin therapy had less progression of disease as reflected by smaller changes in the aortic valve gradient and area than patients not taking statins. At baseline, aortic valve area and mean aortic valve gradient in both the statin and nonstatin group was 1.2 cm2 and 15 mm Hg, respectively; peak gradient was 28 mm Hg in the statin group and 29 mm Hg in those not taking statins. In the statin-treated patients, annualized reduction in aortic valve area was 0.06 cm2 compared to 0.11 cm2 in the nonstatin group (p=0.03), representing 45% less progression per year. Low-density lipoprotein cholesterol fell significantly in the statintreated patients (25% reduction; p<0.04) and was unchanged in the nonstatin patients. There was a modest correlation between the reduction in lowdensity lipoprotein cholesterol and the change in peak gradient (r=0.29; p=0.02) but not with the change in aortic valve area. As the authors note, these intriguing findings require confirmation by a prospective, randomized trial. However, the results of this study are encouraging in that they suggest the potential of a pharmacologic approach to delay progression of a condition for which there is no treatment other than surgery. The rationale of statin therapy in calcific aortic stenosis is recognition that inflammation is a component of the lesion and that statins provide an anti-inflammatory action. The patients in this study are representative of those with calcific aortic stenosis, in that progression of the lesion in the nonstatin group was −0.1cm2 per year, consistent with that recognized in this population in prior studies. Further evaluation of the potential therapeutic effects of statins in aortic stenosis is awaited.
No takes yet. Share an insight, caveat, or question.
Ezra A. Amsterdam (2002) conducted an observational in mild-moderate calcific aortic stenosis (n=174). Statin therapy vs. No statin therapy was evaluated on annualized reduction in aortic valve area (p=0.03). Statin therapy was associated with less progression of aortic stenosis, with an annualized reduction in aortic valve area of 0.06 cm2 compared to 0.11 cm2 in patients not taking statins.
Synapse has enriched 10 related papers. Consider them for comparative context: